
KOD Stock Forecast & Price Target
KOD Analyst Ratings
Bulls say
Kodiak Sciences is a promising investment with a positive outlook, as the company's ABC platform and investigational medicines have the potential to greatly improve treatment for retinal diseases. With several upcoming catalysts in 2026, including the release of Phase 3 trial data for tarcocimab and KSI-501, we believe the company has the potential for significant growth. Our valuation and risks analysis has resulted in a Buy rating and increased price target, factoring in the potential success of the ABC pipeline, the company's execution history, and positive feedback from key opinion leaders. However, there are risks to consider, such as the failure to secure capital resources and the potential for underperformance of developmental candidates.
Bears say
Kodiak Sciences is reporting positive results for its investigational drug, tarcocimab tedromer, in diabetic retinopathy which validates their reformulated ABC platform design. However, the company's other investigational medicine, KSI-501, also being developed on the ABC platform, only has a 35-60% chance of success in wet AMD and DR. Overall, the positive tarcocimab update may contribute to potential future success, but other factors such as the limited applicability of the ABC platform and the high-risk nature of drug development could still hinder Kodiak's long-term prospects and justify a negative outlook.
This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
KOD Analyst Forecast & Price Prediction
Start investing in KOD
Order type
Buy in
Order amount
Est. shares
0 shares